{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:21:45Z","timestamp":1790698905403,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000032","name":"CIHR III","doi-asserted-by":"publisher","award":["NHC-348216"],"award-info":[{"award-number":["NHC-348216"]}],"id":[{"id":"10.13039\/501100000032","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000032","name":"CIHR III","doi-asserted-by":"publisher","award":["PHE-337680"],"award-info":[{"award-number":["PHE-337680"]}],"id":[{"id":"10.13039\/501100000032","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000032","name":"CIHR III","doi-asserted-by":"publisher","award":["PJT-156066"],"award-info":[{"award-number":["PJT-156066"]}],"id":[{"id":"10.13039\/501100000032","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.jhep.2021.05.028","type":"journal-article","created":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T03:37:00Z","timestamp":1624592220000},"page":"1049-1057","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study"],"prefix":"10.1016","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5681-719X","authenticated-orcid":false,"given":"Naveed Z.","family":"Janjua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0886-9889","authenticated-orcid":false,"given":"Stanley","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Younathan","family":"Abdia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dahn","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terri","family":"Buller-Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prince A.","family":"Adu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4555-7609","authenticated-orcid":false,"given":"Hasina","family":"Samji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Wilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margo","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2486-4781","authenticated-orcid":false,"given":"Zahid A.","family":"Butt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mawuena","family":"Binka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0699-2250","authenticated-orcid":false,"given":"Sofia","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mel","family":"Krajden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2021.05.028_bib1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Blach","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.05.028_bib2","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1186\/s12879-016-1683-z","article-title":"Twin epidemics of new and prevalent hepatitis C infections in Canada: BC Hepatitis Testers Cohort","volume":"16","author":"Janjua","year":"2016","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jhep.2021.05.028_bib3","doi-asserted-by":"crossref","first-page":"817","DOI":"10.7326\/0003-4819-157-9-201211060-00529","article-title":"Hepatitis C virus testing of persons born during 1945-1965: recommendations from the Centers for Disease Control and Prevention","volume":"157","author":"Smith","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2021.05.028_bib4","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2015.07.056","article-title":"Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001-2013","volume":"149","author":"Beste","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.05.028_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183609","article-title":"A\u00a0syndemic approach to assess the effect of substance use and social disparities on the evolution of HIV\/HCV infections in British Columbia","volume":"12","author":"Butt","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2021.05.028_bib6","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.2105\/AJPH.2015.302591","article-title":"Decreasing hepatitis C incidence among a population with repeated tests: British Columbia, Canada, 1993-2011","volume":"105","author":"Kuo","year":"2015","journal-title":"Am J Public Health"},{"key":"10.1016\/j.jhep.2021.05.028_bib7","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2458-13-291","article-title":"Mortality among British Columbians testing for heaptitis C antibody","volume":"13","author":"Yu","year":"2013","journal-title":"BMC public health"},{"key":"10.1016\/j.jhep.2021.05.028_bib8","doi-asserted-by":"crossref","first-page":"102989","DOI":"10.1016\/j.drugpo.2020.102989","article-title":"Drug-related deaths in a population-level cohort of people living with and without hepatitis C virus in British Columbia, Canada","volume":"86","author":"Samji","year":"2020","journal-title":"Int J Drug Pol"},{"key":"10.1016\/j.jhep.2021.05.028_bib9","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.drugpo.2019.06.003","article-title":"What is killing people with hepatitis C virus infection? Analysis of a population-based cohort in Canada","volume":"72","author":"Krajden","year":"2019","journal-title":"Int J Drug Pol"},{"key":"10.1016\/j.jhep.2021.05.028_bib10","series-title":"Provisional Drug Overdose Death Counts","author":"Ahmad","year":"2020"},{"key":"10.1016\/j.jhep.2021.05.028_bib11","series-title":"Drug-related deaths in Scotland in 2019","year":"2020"},{"key":"10.1016\/j.jhep.2021.05.028_bib12","series-title":"Opioids and stimulant-related Harms in Canada","year":"2020"},{"issue":"4","key":"10.1016\/j.jhep.2021.05.028_bib13","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/hep4.1307","article-title":"Effectiveness of ledipasvir\/sofosbuvir and sofosbuvir\/velpatasvir in people who inject drugs and\/or those in opioid agonist therapy","volume":"3","author":"Janjua","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2021.05.028_bib14","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/jvh.13295","article-title":"The impact of SVR from direct-acting antiviral- and interferon-based treatments for HCV on hepatocellular carcinoma risk","volume":"27","author":"Janjua","year":"2020","journal-title":"J\u00a0Viral Hepat"},{"issue":"1","key":"10.1016\/j.jhep.2021.05.028_bib15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2017.08.030","article-title":"HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma","volume":"68","author":"Ioannou","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.05.028_bib16","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents","volume":"153","author":"Kanwal","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.05.028_bib17","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/hep.29408","article-title":"Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease","volume":"69","author":"Backus","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.05.028_bib18","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study","volume":"393","author":"Carrat","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2021.05.028_bib19","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1053\/j.gastro.2018.07.015","article-title":"Incidence of hepatocellular carcinoma after direct antiviral therapy for HCV in patients with cirrhosis included in surveillance programs","volume":"155","author":"Nahon","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.05.028_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150176","article-title":"Assessing hepatitis C burden and treatment effectiveness through the British Columbia hepatitis Testers cohort (BC-HTC): design and characteristics of linked and unlinked participants","volume":"11","author":"Janjua","year":"2016","journal-title":"PloS one"},{"key":"10.1016\/j.jhep.2021.05.028_bib21","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1155\/2012\/947676","article-title":"An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver","volume":"26","author":"Myers","year":"2012","journal-title":"Can J Gastroenterol\u00a0= J canadien de gastroenterologie"},{"key":"10.1016\/j.jhep.2021.05.028_bib22","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"10.1016\/j.jhep.2021.05.028_bib23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.drugpo.2018.02.001","article-title":"Identifying injection drug use and estimating population size of people who inject drugs using healthcare administrative datasets","volume":"55","author":"Janjua","year":"2018","journal-title":"Int J Drug Pol"},{"key":"10.1016\/j.jhep.2021.05.028_bib24","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/aje\/kwv445","article-title":"Long-Term Benefits and\u00a0Adverse Effects of Beta-Interferon for Multiple Sclerosis (BeAMS) Study Group. Comparison of statistical approaches for dealing with immortal time bias in drug effectiveness studies","volume":"184","author":"Karim","year":"2016","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jhep.2021.05.028_bib25","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"10.1016\/j.jhep.2021.05.028_bib26","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A\u00a0proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.jhep.2021.05.028_bib27","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/pds.4325","article-title":"Comparison of the ability of double-robust estimators to correct bias in propensity score matching analysis. A Monte Carlo simulation study","volume":"26","author":"Nguyen","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jhep.2021.05.028_bib28","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1001\/jama.2020.1267","article-title":"Why test for proportional hazards?","volume":"323","author":"Stensrud","year":"2020","journal-title":"JAMA : J Am Med Assoc"},{"key":"10.1016\/j.jhep.2021.05.028_bib29","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/hep.29811","article-title":"Direct-acting antiviral sustained virologic response: impact on mortality in patients without advanced liver disease","volume":"68","author":"Backus","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.05.028_bib30","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jhep.2020.02.022","article-title":"Treatment of HCV reduces viral hepatitis-associated liver-related mortality in patients: an ERCHIVES study","volume":"73","author":"Butt","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.05.028_bib31","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.11055","article-title":"Association of direct-acting antiviral treatment with mortality among medicare beneficiaries with hepatitis C","volume":"3","author":"Kalidindi","year":"2020","journal-title":"JAMA Netw open"},{"key":"10.1016\/j.jhep.2021.05.028_bib32","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/jvh.13232","article-title":"Real-world impact following initiation of interferon-free hepatitis\u00a0C\u00a0regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis","volume":"27","author":"McDonald","year":"2020","journal-title":"J\u00a0viral Hepat"},{"issue":"9","key":"10.1016\/j.jhep.2021.05.028_bib33","doi-asserted-by":"crossref","first-page":"ofaa347","DOI":"10.1093\/ofid\/ofaa347","article-title":"Concurrent hepatitis C and B virus and human immunodeficiency virus infections are associated with higher mortality risk illustrating the impact of syndemics on health outcomes","volume":"7","author":"Butt","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jhep.2021.05.028_bib34","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/cid\/ciz633","volume":"70","author":"Artenie","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2021.05.028_bib35","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.drugpo.2019.05.024","article-title":"Low rate of reinfection among a cohort of people who use drugs successfully treated for hepatitis C virus infection in Vancouver, Canada","volume":"72","author":"Holeksa","year":"2019","journal-title":"Int J Drug Pol"},{"key":"10.1016\/j.jhep.2021.05.028_bib36","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.drugpo.2019.03.001","article-title":"Direct-acting antiviral treatment for hepatitis C, reinfection and mortality among people attending an inner-city community health centre in Victoria, Canada","volume":"72","author":"Selfridge","year":"2019","journal-title":"Int J Drug Pol"},{"key":"10.1016\/j.jhep.2021.05.028_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0207226","article-title":"Beyond interferon side effects: what residual barriers exist to DAA hepatitis C treatment for people who inject drugs?","volume":"13","author":"Madden","year":"2018","journal-title":"PloS one"},{"key":"10.1016\/j.jhep.2021.05.028_bib38","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.4192","article-title":"Assessment of treatment strategies to achieve hepatitis C elimination in Canada using a validated model","volume":"3","author":"Binka","year":"2020","journal-title":"JAMA Netw open"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821004013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821004013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:42:56Z","timestamp":1759174976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827821004013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0168827821004013"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2021.05.028","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2021.05.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}